VMS TMT IPO Day 3: Check GMP, Subscription Status & Key Highlights

19 September 2025
1 min read
VMS TMT IPO Day 3: Check GMP, Subscription Status & Key Highlights
whatsapp
facebook
twitter
linkedin
telegram
copyToClipboard

The bidding window for the ₹148.50 crore VMS TMT IPO will conclude today. The IPO has received a strong response from all the investor categories and got subscribed 21.75 times till the end of Day 2. 

VMS TMT IPO: Issue Details

  • Issue Size: VMS TMT IPO is a book-building issue of ₹148.50 crores, consisting entirely of a fresh issue of 1.50 crore shares.
  • Price Band: The price band is set between ₹94 and ₹99 per share.
  • Book-running lead managers: Arihant Capital Markets Ltd
  • Registrar: Kfin Technologies Ltd
  • Listing: The shares are proposed to be listed on the NSE and the BSE on September 26. 

VMS TMT IPO Day 3: Subscription Details

[19-September-2025 17:00:00]

Investor Category

Subscription (Times)

Qualified Institutional Buyers (QIBs)

120.80

Non-Institutional Investors

227.06

Retail Individual Investors (RIIs)

47.78

Total

102.19

Utilisation of IPO Proceeds

The company aims to use the net proceeds from the fresh issue towards the following objectives: 

  • Repay/prepay company’s outstanding borrowings 
  • General corporate purposes 

VMS TMT IPO GMP Details

As of 19 September 2025, VMS TMT IPO's GMP stood at ₹17. The estimated listing price is ₹116, i.e., a 17.17% gain per share over the upper price band. 

Source:  Business Standard Report dated 19 September 2025

Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market.

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here.

Do you like this edition?